Point72, Cohen Report 0% Stake in OKYO
OKYO Pharma Ltd amendment to a Schedule 13G/A states that Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen each report 0% beneficial ownership of Ordinary Shares as of the close of business on 03/31/2026.
Rhea-AI Filing Summary
OKYO Pharma Ltd amendment to a Schedule 13G/A states that Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen each report 0% beneficial ownership of Ordinary Shares as of the close of business on 03/31/2026. The filing lists the reporting persons' business address and CUSIP G6724L116.
Positive
- None.
Negative
- None.
Insights
Amendment confirms no reported stake as of 03/31/2026.
The amendment restates that Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen beneficially own 0% of OKYO Ordinary Shares as of the close of business on 03/31/2026. The filing formats the cover‑page rows for voting and dispositive power with zeros.
Timing and cash‑flow treatment are not included in the excerpt; subsequent filings would show any changes in holdings.
Filing is a routine ownership amendment with standard disclosures.
The statement identifies the reporting persons, their Delaware/United States citizenship status, and principal business address. Item 4 references cover‑page rows for amounts and voting/dispositive powers "as of the close of business on 03/31/2026."
Because the reported percent is 0%, there is no five‑percent threshold impact; this is an administrative update to ownership records.
Key Figures
Key Terms
Schedule 13G/A regulatory
beneficial ownership regulatory
dispositive power regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does OKYO (OKYO) Schedule 13G/A amendment report?
Who filed the Schedule 13G/A amendment for OKYO?
Does the amendment show any voting or dispositive power for Point72 or Steven A. Cohen?
Is the reported ownership above the 5% reporting threshold?
AI-generated analysis. How Rhea-AI works. Not financial advice.